|
The ABL Advisor Deal Tables
SELECTED TRANSACTION DETAILS
CytoSorbents Enters $20MM Credit Facility with Avenue Capital Group
|
Lenders/Participants
|
Avenue Capital [Lender]
|
|
Structure
|
Term Loan
|
|
Amount
|
$20.000
Million
|
|
Borrower(s)
|
CytoSorbents Corporation
|
|
Description
|
The credit agreement, which has an initial term of three years, provides up to $20 million in total term loan capital including an initial tranche of $15 million, with immediate availability of $10 million and an additional $5 million with the timely acceptance by U.S. FDA of the Company’s planned De Novo application for DrugSorb-ATR and certain liquidity requirements. A second tranche of $5 million would be available in the second half of 2025 with FDA marketing clearance for DrugSorb-ATM to help support an anticipated launch of the therapy in the United States.
|
|
Industry
|
Healthcare
|
| Related Tags |
Avenue Capital Group
|
ABL Advisor
Deal Tables
2025
|
|
|
|